HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc., (OTCBB:OCOL) (Oncolin) announces that one of its lead drug candidates has shown in preclinical testing that it extends the life of animals that have human tumors implanted in their brains. The early testing has yielded results in animals that are equivalent to that of Temodar®, which is one of the leading cancer treatments for brain cancer with annual revenues in excess of $500 million annually. This technology is covered under Oncolin’s recent exclusive option to license from The University of Texas M.D. Anderson.
